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Condensed abstract  
This is the first report on a combined treatment with pegylated interferon α-2a and dacarba-
zine in metastatic melanoma. The regimen was well tolerated with an encouraging remission 
rate of 24%. 
 
Abstract 
 
Background: Dacarbazine (DTIC) and pegylated Interferon -2a have both demonstrated 
some efficacy as single agents in metastatic melanoma. This study is the first to test a combi-
nation in a phase II trial. 
Patients and methods: 28 stage IV melanoma patients without brain metastases were treated 
with DTIC (850mg/m2 3-weekly) combined with weekly 180µg pegylated Interferon -2a 
(Pegasys® ). The study was initiated to evaluate the efficacy and tolerability of the combina-
tion. Primary study endpoint was objective response. 
Results: 25 patients were evaluable for response. Two patients (8.0%) achieved a complete 
response ongoing for more than 480 and 746 days, respectively. Four patients (16.0%) dem-
onstrated a partial response, another patient a disease stabilization. 6/7 non-progressive pa-
tients had either not received or not progressed during adjuvant interferon treatment for stage 
II/III. Median duration of response was 236 days, progression-free survival 56 days, and 
overall survival time was 403 days. Few grade 3 and only one grade 4 toxicity were observed.  
Conclusions: The combination of DTIC and pegylated interferon -2a was well tolerated in 
metastatic melanoma patients. The response rate of 24% including two long-lasting complete 
remissions is encouraging, but has to be confirmed in larger trials. 
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Introduction 
Despite significant improvement in the early detection and treatment of malignant melanoma 
in recent years, there has been little progress in an enhancement of response rates and survival 
times in patients with advanced metastatic melanoma (AJCC classification, stage IV) 1. The 
median survival time remains still in a range of 6 to 12 months 2. Complete responses are lim-
ited to a small subset of patients which cannot be exactly characterized and predicted by now. 
After three decades of clinical trials Dacarbazine (DTIC) is still considered as a reference 
drug. Prospectively-randomized trials on DTIC as a single agent have demonstrated response 
rates in a range of 6 to 12% in the recent years without a clear impact on overall survival 3, 4. 
Therefore, surgical resection of metastases and multidisciplinary approaches including radio-
therapy for palliative care are still treatment options of first choice. Immunotherapeutic ap-
proaches using recombinant cytokines like interferons or interleukin-2 have not demonstrated 
a clear benefit to Dacarbazine alone. A biochemotherapy regimen containing Interferon , 
Interleukin-2 and three different cytotoxic drugs (CVD scheme) has also failed to increase 
survival rates overview in 2. Therefore it is widely accepted that the therapy of choice in 
patients with advanced metastatic melanoma is a treatment within a clinical trial, in order to 
gain knowledge on new therapeutic options with more efficacy in this disease. 
 
Recombinant interferons have been proven to demonstrate limited anti-tumor activity in pa-
tients with metastatic melanoma as single agents. Furthermore, they are widely used for the 
adjuvant treatment of malignant melanoma with benefits in relapse-free survival and small 
impact on overall survival 5-7.  
The combination of Dacarbazine (DTIC) and recombinant Interferon  has been studied in-
tensively during the last 15 years. Despite numerous clinical trials and a meta-analysis on this 
combination regimen, it appears that this combination is only affecting the response rate but 
not the overall survival time 8. Therefore, there is a clear medical need for more effective drug 
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combinations. One potential disadvantage of recombinant interferons are the post-injectional 
peaks in the serum concentration which are associated with flu-like symptoms some hours 
after drug exposure. The relatively short half-life of recombinant interferon  required a new 
drug formulation which would be more acceptable for a long-term treatment and constant 
drug levels 9. 
 
Recombinant human PegInterferon -2a (PEG-IFN-2a; Pegasys; Hoffmann-La Roche Inc., 
Nutley, ND, USA) is a form of Interferon -2a modified by the covalent attachment of a 
branched 40-KD metoxipolyethyleneglucolmoiety. Already licensed for use in chronic hepati-
tis C, studies in this population found that PEG-IFN-2a has superior efficacy compared to 
non-pegylated Interferon . The long half-life of PEG-IFN-2a allows a more convenient 
once-weekly dosing regimen with improved tolerability. Formation of binding or neutralizing 
antibodies against PEG-IFN-2a is rare and occurs only in 2-6% of patients 10, 11. Apart from 
phase I/II clinical trials conducted in renal cell cancer and hematologic malignancies, there is 
only one clinical trial on pegylated IFN-2a in melanoma published yet 12. 
Here we report on the results of the first prospective, open-label phase II trial combining 
Dacarbazine with pegylated Interferon -2a. 
 
Patients and Methods 
Patients 
Patients eligible for this clinical trial provided written informed consent and have fulfilled the 
following inclusion criteria: 
Age ≥ 18 and ≤ 75 years, ECOG scale 0-2, confirmed metastatic melanoma (stage IV, AJCC 
classification) 1, at least one uni-dimensionally measurable lesion according to RECIST crite-
ria, minimum indicator lesion size of > 10mm, wash-out period of 4 weeks for previous inter-
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feron treatment. Patients with adjuvant previous interferon treatment were accepted, but not 
those with pegylated interferon treatment or those with tumor progression to stage IV disease 
during interferon therapy. Patients with mucosal, ocular or melanoma of unknown origin were 
excluded. Pregnant or lactating women have not been treated. Patients should not have an 
evidence for brain metastases in the basic examinations. Patients with a history of malignan-
cies other than basal cell carcinoma or squamous cell carcinoma or carcinoma in situ of the 
cervix were excluded. Patients with a history of severe cardiac disease (NYHA, III/IV) myo-
cardial infarction within the last 6 months or ventricular tachyarrhythmia requiring ongoing 
treatment or unstable angina were not included. Further exclusion criteria: medical history of 
severe psychiatric diseases especially depression, seizure disorders requiring anti-convulsant 
treatment, history of poorly-controlled thyroid dysfunctions, known infections with hepatitis 
B or C or HIV, patients with immune diseases except for rheumatoid arthritis, patients with 
abnormal baseline hematologic laboratory parameters (Hb <10g/dl, WBC < 4/nl, platelets < 
100/nl, bilirubin > 1.5 ULN (upper limit of normal), ALT/AST > 2.5 ULN, ALP > 2.5 ULN 
or serum-creatinin > 1.5 ULN. Patients should have a life expectancy of at least three months. 
 
Protocol design and treatment 
This 3-centre, open-label phase II study of DTIC plus pegylated Interferon -2a was approved 
by the ethics committee of each participating centre and their respective authorities. 
Dacarbazine (DTIC) was given intravenously at a dose of 850mg/m2 every 3 weeks for a 
maximum of up to 25 weeks. Pegylated interferon -2a was given at a dose of 180µg once 
weekly subcutaneously for up to 25 weeks. If subjects did not present progressive disease at 
the end of the 25 week period, they were allowed to continue until progression in an inde-
pendent Expended Assess Program (EAP) for an undefined period of time. In the absence of 
NCI-CTC toxicity criteria greater than grade 1, DTIC therapy was repeated every 3 weeks, for 
  
6
6
subjects not tolerating 180µg of pegylated interferon -2a, the dose had been reduced to 90µg 
and maintained at this level, if tolerated until disease progression. 
Any subject who experienced grade 2 laboratory abnormalities or adverse events should 
maintain on the assigned dose if possible. For subjects experiencing grade 2 elevation of 
ALT, pegylated interferon -2a should be temporarily stopped. Subjects experiencing grade 2 
flu-like symptoms should continue pegylated interferon -2a and DTIC treatment. Pegylated 
interferon -2a and/or DTIC should be temporarily stopped and/or reduced if a subject ex-
perienced ≥ grade 3 laboratory abnormalities (except for elevated ALT), grade 4 fever, chills 
or other flu-like symptoms, ≥ grade 3 adverse events (except for flu-like symptoms) or grade 
2 elevated ALT. 
This phase II study was initiated to evaluate the tolerability, safety and efficacy of the com-
bined treatment regimen. The primary endpoint was the evaluation of the response rate. 
 
Response and toxicity assessment 
All patients had dense follow-up evaluation during the study conduction. Tumor response was 
assessed using the RECIST criteria 13. Patients with objective responses (CR and PR) were re-
evaluated by an independent radiological (Prof. Dr. Delorme, Radiology Department, DKFZ 
Heidelberg, Germany). At initiation, in weeks 9, 17 and 25 and at the follow-up visits thereaf-
ter, the following imaging evaluations were used: brain CT or MRI, CT of the chest and ab-
domen, lymph-node ultrasound and bone scintigraphy. Other investigations have been used if 
clinically indicated. Patients received questions on their medical history and a complete body 
examination including vital signs and ECG (if mandatory). The performance status was as-
sessed according to the ECOG status scale. Laboratory tests included hematology, blood 
chemistry, urine analyses, thyroid tests and a pregnancy test in pre- and peri-menopausal 
women. Blood was obtained during the weekly visits for the first 4 weeks, then every 3 weeks 
until the end of treatment, additionally, once in week 9 and 17. Three-monthly visits were 
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performed thereafter in the follow-up period. The visits in week 2 and 3 could be performed 
outside of the study centers, for instance by the treating general practitioner. All other clinical 
visits were required to be done in the respective study centre.  
 
Statistical analyses 
Due to the single-arm design of the study, a conservative approach for the primary analysis of 
safety and efficacy was made. The definition of the analysis population and the replacement 
of missing values have been considered. The selection of the sample size was based on practi-
cal considerations and not on power calculations. The study was designed to prove the feasi-
bility of combined pegylated interferon -2a to Dacarbazine. Instead of p-values of prede-
fined hypothesis, 95% confidence intervals (2-sided) have been calculated for the main safety 
and efficacy parameters. An intention to treat tolerability, safety and efficacy assessment was 
defined for all subjects who received at least one dose of the combination of Dacarbazine and 
pegylated interferon -2a. The per-protocol analysis included all subjects who were meeting 
the criteria for the ITT safety population and had no major protocol violations in a way that 
could influence the assessment of efficacy. Major protocol violations included inadequate 
information on tumor response, inadequate patient compliance defined as missing of two or 
more consecutive doses or missing more than 20% of the projected injections at time of with-
drawal and lastly treatment duration of less than 25 weeks with the exception of progressive 
tumor response being the reason for withdrawal. 
The survival rates including time to progression and time to death were analyzed by a Kaplan-
Meier analysis in the intent-to-treat efficacy populations only. This type of analysis considers 
subjects lost to follow-up as censored observations. Additionally, more conservative survival 
rates have been calculated for the 3-, 6-, 9- and 12-months follow-up visits assuming subjects 
lost to follow-up as died at date of the last contact. 
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In the analysis of the safety data, the incidence of adverse events has been calculated at the 
preferred term level and the organ system level according to the classification of MeDRA. 
The same analysis has been done for the drug-related adverse events. Furthermore, adverse 
events were presented in individual subject listings, which included intensity, and relationship 
to the study drugs and were appropriate to the NCI-CTC grades. 
All patients´ case report forms (CRFs) were monitored on-site at the participating centers by 
independent monitors. 
 
RESULTS 
Patients´ characteristics 
Between August 2004 and September 2006 a total of 28 patients were included into this 
study. 20/28 patients (71.4%) were AJCC stage IV M1c, the remaining study patients were 
classified as M1b (28.6%). 39.3% of patients had an elevated LDH prior to treatment initia-
tion. Of 16 males and 12 females with a median age of 56 years, 50% were interferon-naïve, 
which means they did not receive interferon as an adjuvant treatment for stage II/III. The 
clinical characteristics of the entire study population are summarized in table 1. 
 
Treatment administration 
A median of three cycles for DTIC and nine applications of subcutaneous pegylated interferon 
-2a were given over nine weeks. The mean treatment duration was 103.5 days, the median 
was 62 days. The reasons for treatment discontinuation were progressive disease in all but one 
patients. Only one patient (ID-No. 03-02; table 1) had an adverse event-related discontinua-
tion. The 43-year old female patient demonstrated a complete response of her lung metastases 
after 9 weeks (= 3 cycles) of treatment. Due to an unacceptable dizziness (CTC grade 2) she 
refused treatment continuation. However, at the end of the study observation period she was 
still in a complete remission without further treatment. 
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Response evaluation and survival 
From 28 patients enrolled into this study, 25 were evaluable for efficacy parameters. Three 
patients were inevaluable due to withdrawal of study consent and refusal of any re-evaluations 
and follow-up investigations. Two patients (8.0%) demonstrated a complete response (CR), 
still lasting for more than 480 and 637 days, respectively. The CRs have been re-confirmed by 
an independent radiological review committee. Both patients did not receive adjuvant inter-
feron treatment before they progressed to stage IV disease. 
Four patients (16.0%) demonstrated partial responses lasting for up to 384 days (median: 236 
days). The lung was the predominantly affected organ in these patients, but two of the four 
PRs were observed in the adrenal glands, peritoneum and skin, too. Two of the four patients 
received adjuvant interferon treatment, but only one progressed during this treatment to stage 
IV melanoma.  
In one patient, a stabilized disease for 56 days was observed. This patient was interferon-
naive prior to the study initiation. The median time to first response was 67.5 days, the dura-
tion of response 236 days. Progression-free survival was calculated as 56 days in median. The 
median overall survival time was 403 days. Details on the outcome parameters are shown in 
table 2. 
 
Safety evaluation 
All 28 patients included into the study were evaluable for safety parameters. Table 3 is sum-
marizing all treatment-related adverse events showing the most intensive severity. There was 
only one grade 4 leucopenia, which spontaneously resolved after interruption of interferon 
treatment. All grade 3 events recovered after dose delays or treatment discontinuation due to 
progressive disease, too. Dose reductions of pegylated interferon -2a were performed in 7 
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patients (28%), while 3 patients (12%) needed dose reductions for DTIC. Life-threatening 
adverse event were not observed. 
 
DISCUSSION 
Pegylation of therapeutic proteins is a well established method for delaying clearance and 
reducing protein immunogenicity. Pegylated proteins have been demonstrated to be safe and 
effective in humans 9. Pharmacokinetic and pharmacodynamic data obtained from animals 
and a phase I study in healthy volunteers indicated that pegylated interferon -2a injected 
once a week has potential for superior efficacy for hepatitis as compared to conventional in-
terferon injected three times a week (Roche Pharma AG, investigator broschure). Studies with 
pegylated interferon -2a in renal cell cancer (RCC) and chronic myeloid leukemia (CML) 
yielded an overall response rate of 13.4% and a median overall survival of 16 months for 
monotherapy (RCC) 14 and a major cytogenetic response in 35% for pegylated interferon -2a 
compared to 18% for standard interferon treatment (CML) 15, respectively. Side effects of 
pegylated interferon -2a were comparable with conventional interferon -2a with a trend in 
favor for the pegylated interferon 15. 
The only study in metastatic melanoma compared three different dose cohorts of pegylated 
interferon -2a in 150 patients. An open-label, randomized, phase II trial evaluated the safety, 
tolerability and efficacy of subcutaneous PEG-IFN-2a in patients with stage IV metastatic 
melanoma. PEG-IFN-2a was administered subcutaneously at 180µg, 360µg, or 450µg for a 
maximum of 24 weeks. Response rates between 6 and 12% and an overall survival between 
217.5 and 322 days were obtained for the three dosing groups. PEG-IFN-2a at 180µg was 
tolerated by most patients, but treatment withdrawals were more pronounced in the 360 and 
450µg dose groups (19% and 16%) in contrast to the 180µg PEG-IFN-2a group (6%) 12. 
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Although there was a trend to a higher response rate and longer survival for the high-dose 
groups (360µg and 450µg pegylated interferon -2a) compared to 180µg once weekly, it was 
questionable whether this was linked to the dose levels or to different patients´ characteristics 
in the three groups 12. Since the dose-response relationship was unclear and serious adverse 
events leading to withdrawal of patients were more often seen in the higher dose level, 180µg 
once weekly pegylated interferon -2a was chosen for this clinical trial combined with a 
chemotherapeutic agent, Dacarbazine. It was hypothesized that the improved pharmacokinetic 
profile of pegylated interferon -2a in conjunction with Dacarbazine may increase the tumor 
response rates and possibly the survival rate without increasing toxicity.  
Our study is the first trial combining pegylated Interferon -2a with standard-dosed Dacarba-
zine in metastatic melanoma. The response rate of 24 % is interesting because the majority of 
patients (71.4%) suffered from stage M1c and furthermore, half of the patients were already 
pre-treated with conventional interferon  in the adjuvant setting. All responses (2 CRs and 4 
PRs) have been confirmed by an independent review.  
Of six patients with clinical responses and one patient with a stabilized disease as best re-
sponse only two patients were not interferon-naïve and only one patient demonstrated a pro-
gression during adjuvant interferon treatment. Six of seven patients with a tumor progression 
during adjuvant conventional interferon treatment showed also a progressive disease during 
pegylated interferon 2a therapy. However, it is still speculative to argue that the probability 
of a clinical benefit from pegylated interferon 2a is higher in interferon-naïve patients. The 
interpretation of our trial results is limited due to the relatively low number of patients in-
cluded into this phase II trial. Of interest, the results of our trial confirm that durable complete 
responses can be found in studies combining conventional chemotherapeutic agents with pe-
gylated interferon . A meta-analysis of more than 3000 patients from multiple randomized 
trials by Huncharek et al concluded that the combination of Dacarbazine with conventional 
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interferon  is capable of producing response rates greater than with DTIC monotherapy 
alone 8. However, the impact on the overall survival time is still unclear and needs clearly to 
be demonstrated in a phase III trial design. 
Temozolomide has also been combined with conventional interferon . A prospective-
randomized phase III trial from Germany and Switzerland compared the combination to Te-
mozolomide alone. Kaufmann et al demonstrated 13.4% partial or complete remissions in the 
monotherapy arm in contrast to 24.1% for Temozolomide and conventional interferon 2b. 
There was only a slight trend to an improvement of overall survival which accounted for 8.4 
months for single-agent treatment versus 9.7 months for the combination 16. 
Since our phase II trial was not comparing different regimens, it is difficult to draw final con-
clusions. However, it is obvious that the safety profile of combined pegylated interferon -2a 
and Dacarbazine is convenient with few grade 3 and 4 toxicities. Also, the number of discon-
tinuations due to treatment-related adverse events was comparably low. In the single-agent 
pegylated IFN2a trial of Dummer et al, dose reductions or dose delays due to adverse events 
or laboratory abnormalities occurred in 23% of the patients treated in the 180µg group. 6% of 
the patients needed a treatment withdrawal in this group 12. 
In conclusion, it seems that the combination with Dacarbazine is not significantly adding to 
the toxicity of pegylated interferon -2a alone and is well-tolerated in general. However, the 
combination of Dacarbazine with pegylated interferon -2a enhances the single-agent activity 
of pegylated interferon -2a significantly. It can not be excluded that patient selection plays a 
role for the promising response rate in this relatively small phase II trial performed in only 
three melanoma centers. However, 71.4% of our patients were belonging to stage M1c and 
none of the patients to M1a. Interestingly, in this clinical trial six out of seven patients with 
clinical responses or stabilization were either interferon-naive or failed to progress to stage IV 
disease during adjuvant interferon treatment. This observation indicates the need of further 
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investigation of predictive criteria of a treatment response to interferons. The finding of this 
pilot trial could eventually lead to a careful consideration of the pre-treatment modalities in 
forthcoming, interferon-based, first-line trials for stage IV melanoma patients. 
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TABLES 
Table 1 
Overview on 25 evaluable patients: characteristics and treatment outcome 
                         
Pat-ID Age / 
Gender 
Adj. IFN 
yes*1/no 
AJCC stage IV 
subcategories 
LDH 
 
Metastases localizations Best 
response 
Response 
duration 
 
Survival time 
[days] 
01-01 48 / M no M1c Normal Head and Neck, Liver, Lung, 
Lymph Node 
PD  64 
01-02 63 / F no M1c Normal Liver, Lung, Spleen PD  224 
01-03 47 / F no M1b Normal Lung PD  716 
01-05 60 / M no M1c Elevated Bone, Liver, Lung PD  144 
01-06 67 / M yes*1 M1b Normal Lung PD  403 
01-07 68 / M no M1b Normal Lung PD  288 
01-08 67 / M yes*1 M1b Normal Lung PD  408 
01-09 68 / M  M1c Elevated Liver, Lung, Lymph Node PD  Lost to follow 
up after 138 d 
01-10 57 / F yes*1 M1c Normal Lung, Lymph Node PD  629+ (alive) 
01-11 56 / M yes*1 M1c Elevated Liver, Lymph Node PD  166 
02-01 49 / F yes*1 M1b Normal Lung PR 3 472 
02-02 69 / M yes M1c Elevated Adrenals, Lung, Lymph 
Node, Retroperitoneal mass, 
Skin 
PR 88 366 
02-03 47 / M no M1c Normal Adrenals, Lung, Lymph 
Node, Peritoneum, Skin 
PR 384 560 
02-04 48 / M yes*1 M1c Normal Liver, Lung, Lymph Node, 
Skin 
PD  725 
02-05 47 / F no M1c Elevated Bone, Breast, Lung, Retrop-
eritoneal mass, Skin 
PD  222 
02-06 42 / M yes M1c Normal Lung, Lymph Node PD  408 
02-07 43 / F yes M1c Normal Ascites, Lung, Lymph Node SD 56 608+ (alive) 
03-01 43 / F no M1b Normal Lung CR 637 + 
(ongoing) 
746+ (alive) 
03-02 49 / F yes M1c Elevated Bone, Lung, Lymph Node, 
Muscles 
PD  273 
03-03 58 / M yes M1c Elevated Colon, Lymph Node, Mus- PD  567+ (alive) 
  
1 
1 
cles, Skin 
03-04 60 / M no M1b Normal Lung PD  322 
03-05 43 / F no M1c Elevated Bone, Liver, Lymph Node PD  86 
03-06 47 / F yes*1 M1c Elevated Bone, Breast, Colon, Lung, 
Muscles 
PD  145 
03-07 68 / M no M1b Normal Lung, Muscles PR 73 384 
03-08 58 / M no M1c Elevated Lung CR 480 + 
(ongoing) 
588+ (alive) 
                                          
*1Patients with progressive disease leading to stage IV during adjuvant interferon treatment 
Table 2 
Efficacy evaluation (25 patients) 
  
Best response n % 
CR 2 8.0 
PR 4 16.0 
SD 1 4.0 
PD 18 72.0 
Total 25 100.0 
 
Outcome n Median (days) Range (days) 
Time to first response (CR + PR) 6 67.5 57-113 
Duration of response (CR + PR) 6 236 3-637 
Time to progressive disease 23 57 52-449 
Progression free survival (PFS) 
 
25 56 
 
55-71 (95% CI) 
Overall survival 
 
25 403 
 
237-560 (95% CI) 
 
Table 3 
Treatment-related AE's (NCI-CTC criteria), most intensive severity per AE and patient 
(n=28) 
 
Adverse events Total Mild/ 
grade 1 
Moderate/ 
grade 2 
Severe/ 
grade 3 
Life-threatening/
grade 4 
 n n n n n 
Leucopenia/Neutropenia 10 . 8 1 1 
Nausea 9 4 5 . . 
Headache 5 . 3 2 . 
Diarrhea 4 4 . . . 
Dizziness 4 2 1 1 . 
Fatigue 4 1 2 1 . 
Back pain 3 2 1 . . 
Depression 3 2 1 . . 
Hyperhidrosis 3 1 2 . . 
Myalgia 3 1 1 1 . 
Parosmia 3 2 1 . . 
Thrombocytopenia 3 2 . 1 . 
Vomiting 3 . 3 . . 
Alopecia 2 1 1 . . 
Anorexia 2 1 1 . . 
Influenza 2 2 . . . 
Pyrexia 2 2 . . . 
Rigors 2 1 1 . . 
Abdominal pain 1 . 1 . . 
Increased liver enzymes 1 . . 1 . 
Anemia 1 . 1 . . 
Constipation 1 . 1 . . 
Dysgeusia 1 1 . . . 
Gamma-GT increase 1 . . . . 
Hiccups 1 . . . . 
Infusion site swelling 1 1 . . . 
Keratoconjunctivitis sicca 1 1 . . . 
Nasopharyngitis 1 1 . . . 
Pain in extremity 1 . . . . 
Palpitations 1 . . . . 
Photosensitivity reaction 1 1 . . . 
Rash 1 1 . . . 
Sneezing 1 1 . . . 
Purulent sputum  1 . . . . 
Vertigo 1 . . . . 
Blurred vision  1 . . . . 
Decreased weight  1 . . . . 
 
 
